Business Context and Reporting Period
This Form 8-K was filed by Reneo Pharmaceuticals, Inc. (not Onkure Therapeutics, Inc.) on May 7, 2024. The filing serves to announce the Company's financial results for the first quarter ended March 31, 2024, and provides a business update. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Irvine, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were issued in a press release (Exhibit 99.1) but does not contain the detailed financial data within the body of the 8-K itself.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The document references a press release for the specific operational and financial updates but does not summarize the variances or trends within the 8-K text.
Guidance, Outlook, and Risks
The filing indicates that a business update was provided alongside the financial results in the referenced press release. However, the 8-K text does not contain specific guidance, outlook figures, management commentary, or a list of risks and contingencies. It explicitly states that the information in Item 2.02 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the correct registrant name is Reneo Pharmaceuticals, Inc. (Ticker: RPHM), as the input metadata incorrectly listed "Onkure Therapeutics, Inc."
- Review Exhibit 99.1 (the Press Release dated May 7, 2024) to obtain actual Q1 2024 financial figures, as they are absent from this summary document.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting standards.
- Note that the financial information in this filing is not incorporated by reference into other SEC filings unless expressly stated.